Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.62 |
| ▸ | BRD4 | O60885 | 1/20 | 0.60 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MMP12 | P39900 | 1/20 | 0.50 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10130365 | 1.00 | PARP1 (0.62) | PARP1BRD4CREBBPUSP2GAA | |
| SCHEMBL5670717 | 1.00 | PARP1 (0.62) | PARP1BRD4CREBBPUSP2GAA | |
| SCHEMBL5672049 | 0.86 | PARP1 (0.62) | PARP1BRD4CREBBPUSP2GAA | |
| SCHEMBL3641602 | 0.81 | PARP1 (0.60) | PARP1BRD4CREBBPUSP2GAA | |
| SCHEMBL3600753 | 0.81 | PARP1 (0.60) | PARP1BRD4CREBBPUSP2GAA | |
| SCHEMBL30991586 | 0.81 | PARP1 (0.60) | PARP1BRD4CREBBPUSP2GAA | |
| SCHEMBL2104033 | 0.81 | PARP1 (0.60) | PARP1BRD4CREBBPUSP2GAA | |
| SCHEMBL496236 | 0.81 | PARP1 (0.60) | PARP1BRD4CREBBPUSP2GAA | |
| SCHEMBL292432 | 0.81 | PARP1 (0.60) | PARP1BRD4CREBBPUSP2GAA | |
| SCHEMBL5670852 | 0.81 | PARP1 (0.60) | PARP1PDE3BPDE3ATSHRSMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4561561-A2 | SUBSTITUTED 3,4-DIHYDROQUINOLINONE INHIBITORS OF TSHR | Septerna, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026076-A2 | SUBSTITUTED 3,4-DIHYDROQUINOLINONE INHIBITORS OF TSHR | SEPTERNA, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-1955697-B1 | 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8106190-B2 | 2-aminobenzamide derivatives | ASTELLAS PHARMA INC. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-8106190-B2 | 2-aminobenzamide derivatives | ASTELLAS PHARMA INC. (JP) | 2012-01-31 | — | — | US | disclosed |
| WO-2010123139-A1 | ARYLCARBOXAMIDE DERIVATIVE HAVING SULFAMOYL GROUP | 持田製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1955697-A1 | 2-AMINOBENZAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | TRPV1, TRPV2, TRPV5 | PARP1 2763/4885BRD4 275/4885CREBBP 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.